mch10q-063007.htm
Table of Contents





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 10-Q

[ü]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2007

OR

[ ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from . . . . . . . . . . to . . . . . . . . . .

Commission file number 1-12091




MILLENNIUM CHEMICALS INC.
(Exact name of registrant as specified in its charter)




Delaware
22-3436215
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
   
Two Greenville Crossing, 4001 Kennett Pike
19807
Suite 238, Greenville, Delaware
(Zip Code)
(Address of principal executive offices)
 

Registrant's telephone number, including area code:  (713) 652-7200



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes __  No ü

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.  See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.
(Check one):      Large accelerated filer __             Accelerated filer __            Non-accelerated filer ü

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes __No ü

Number of shares of common stock outstanding as of June 30, 2007: 661.  There is no established public trading market for the registrant’s common stock.

The Registrant meets the conditions set forth in General Instructions H(1)(a) and (b) of Form 10-Q and, therefore, is filing this form with a reduced disclosure format.


PART I.  FINANCIAL INFORMATION

ITEM 1.  CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

MILLENNIUM CHEMICALS INC.

CONSOLIDATED STATEMENTS OF INCOME


   
For the three months ended
   
For the six months ended
 
   
June 30,
   
June 30,
 
Millions of dollars
 
2007
   
2006
   
2007
   
2006
 
Sales and other operating revenues:
                       
Trade
  $
146
    $
133
    $
280
    $
260
 
Related parties
   
15
     
20
     
33
     
37
 
     
161
     
153
     
313
     
297
 
Operating costs and expenses:
                               
Cost of sales
   
142
     
134
     
264
     
280
 
Selling, general and administrative expenses
   
22
     
11
     
34
     
22
 
Research and development expenses
   
1
     
1
     
2
     
2
 
     
165
     
146
     
300
     
304
 
 
Operating income (loss)
    (4 )    
7
     
13
      (7 )
                                 
Interest expense
    (19 )     (19 )     (38 )     (31 )
Interest income
   
6
     
1
     
7
     
2
 
Other income (expense), net
    (16 )    
20
      (16 )     (5 )
Income (loss) from continuing operations before
equity investment and income taxes
    (33 )    
9
      (34 )     (41 )
Income from equity investment
in Equistar Chemicals, LP
   
3
     
38
     
6
     
113
 
Income (loss) from continuing operations
before income taxes
    (30 )    
47
      (28 )    
72
 
Provision for (benefit from) income taxes
    (13 )    
2
      (12 )     (5 )
 
Income (loss) from continuing operations
    (17 )    
45
      (16 )    
77
 
Income from discontinued operations, net of tax
   
283
     
69
     
297
     
70
 
 
Net income
  $
266
    $
114
    $
281
    $
147
 
 
See Notes to the Consolidated Financial Statements.


MILLENNIUM CHEMICALS INC.

CONSOLIDATED BALANCE SHEETS


Millions of dollars
 
June 30,
2007
   
December 31,
2006
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
  $
33
    $
76
 
Accounts receivable:
               
Trade, net
   
109
     
96
 
Related parties
   
19
     
15
 
Inventories
   
92
     
87
 
Prepaid expenses and other current assets
   
27
     
13
 
Deferred tax assets
   
38
     
62
 
Notes receivable from Equistar Chemicals, LP
   
500
     
- -
 
Current assets held for sale
   
- -
     
661
 
Total current assets
   
818
     
1,010
 
                 
Property, plant and equipment, net
   
121
     
129
 
Investment in Equistar Chemicals, LP
   
446
     
470
 
Goodwill, net
   
49
     
49
 
Other assets, net
   
71
     
62
 
Long-term assets held for sale
   
- -
     
694
 
 
Total assets
  $
1,505
    $
2,414
 
                 
                 
LIABILITIES AND STOCKHOLDER’S EQUITY
               
Current liabilities:
               
Accounts payable:
               
Trade
  $
72
    $
84
 
Related parties
   
30
     
18
 
Accrued liabilities
   
152
     
72
 
Current liabilities associated with assets held for sale
   
- -
     
335
 
Total current liabilities
   
254
     
509
 
Long-term debt
   
391
     
767
 
Other liabilities
   
255
     
381
 
Deferred income taxes
   
261
     
248
 
Long-term liabilities associated with assets held for sale
   
- -
     
361
 
Commitments and contingencies
               
Minority interest
   
5
     
5
 
Stockholder’s equity:
               
Common stock, $0.01 par value,
  1,000 shares authorized, 709 shares issued
   
- -
     
- -
 
Additional paid-in capital
   
1,176
     
1,176
 
Retained deficit
    (602 )     (840 )
Accumulated other comprehensive loss
    (145 )     (103 )
Treasury stock, at cost (48 shares issued)
    (90 )     (90 )
Total stockholder’s equity
   
339
     
143
 
 
Total liabilities and stockholder’s equity
  $
1,505
    $
2,414
 
 
See Notes to the Consolidated Financial Statements.


MILLENNIUM CHEMICALS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS


   
For the six months ended
June 30,
 
Millions of dollars
 
2007
   
2006
 
Cash flows from operating activities:
           
Net income
  $
281
    $
147
 
Income from discontinued operations, net of tax
    (297 )     (70 )
Adjustments to reconcile net income to
  cash provided by (used in) operating activities:
               
Depreciation and amortization
   
17
     
13
 
Equity investment in Equistar Chemicals, LP –
               
Amount included in net income
    (6 )     (113 )
Distributions of earnings
   
6
     
89
 
Deferred income taxes
   
38
      (48 )
Debt prepayment premiums and charges
   
14
     
7
 
Changes in assets and liabilities that provided (used) cash:
               
Accounts receivable
    (17 )    
12
 
Inventories
    (5 )    
20
 
Accounts payable
    (1 )    
11
 
Other, net
    (129 )    
35
 
Net cash provided by (used in) operating activities – continuing operations
    (99 )    
103
 
Net cash used in operating activities – discontinued operations
    (120 )     (20 )
Net cash provided by (used in) operating activities
    (219 )    
83
 
 
Cash flows from investing activities:
               
Advances under loan agreements to Equistar Chemicals, LP
    (500 )    
- -
 
Expenditures for property, plant and equipment
    (6 )     (5 )
Payments to discontinued operations
    (104 )     (32 )
Distributions from affiliates in excess of earnings
   
24
     
- -
 
Other
   
3
     
1
 
Net cash used in investing activities – continuing operations
    (583 )     (36 )
Net proceeds from sale of discontinued operations
  before required repayment of debt
   
1,089
     
- -
 
Other net cash provided by investing activities – discontinued operations
   
89
     
9
 
Net cash provided by (used in) investing activities
   
595
      (27 )
 
Cash flows from financing activities:
               
Repayment of long-term debt
    (390 )     (241 )
Other
   
1
      (1 )
Net cash used in financing activities – continuing operations
    (389 )     (242 )
Debt required to be repaid upon sale of discontinued operations
    (99 )    
- -
 
Other net cash provided by financing activities – discontinued operations
   
23
     
5
 
Net cash used in financing activities
    (465 )     (237 )
Effect of exchange rate changes on cash
   
1
     
2
 
 
Decrease in cash and cash equivalents
    (88 )     (179 )
Cash and cash equivalents at beginning of period
   
121
     
279
 
Cash and cash equivalents at end of period
   
33
     
100
 
Less: Cash and cash equivalents at end of period – discontinued operations
   
- -
     
44
 
Cash and cash equivalents at end of period – continuing operations
  $
33
    $
56
 


See Notes to the Consolidated Financial Statements.

3

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

TABLE OF CONTENTS
 
 
1.
 
 
5
 
2.
 
 
5
 
3.
 
 
5
 
4.
 
 
6
 
5.
 
 
7
 
6.
 
 
8
 
7.
 
 
9
 
8.
 
 
9
 
9.
 
 
9
 
10.
 
 
10
 
11.
 
 
10
 
12.
 
 
11
 
13.
 
 
11
 
14.
 
 
12
 
15.
 
 
15
 
16.
 
 
15
 
17.
 
 
17
 
18.
 
 
17

4

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

1.  Basis of Preparation
 
The accompanying consolidated financial statements are unaudited and have been prepared from the books and records of Millennium Chemicals Inc. and its subsidiaries (collectively, “Millennium”) in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial information.  Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation have been included.  For further information, refer to the audited consolidated financial statements and notes thereto included in the Millennium Current Report on Form 8-K dated May 29, 2007.
 
Certain previously reported amounts have been reclassified to present Millennium’s inorganic chemicals business as discontinued operations.  Unless otherwise indicated, information presented in the notes to the financial statements relates only to Millennium’s continuing operations.  Information related to Millennium’s discontinued operations is presented in Note 4.
 
 
2.  Company Ownership
 
On November 30, 2004, Lyondell Chemical Company (“Lyondell”) acquired Millennium in a stock-for-stock business combination.  As a result of the business combination, Millennium is a wholly owned subsidiary of Lyondell.  The consolidated financial statements of Millennium reflect its historical cost basis and, accordingly, do not reflect any purchase accounting adjustments related to the acquisition by Lyondell.
 
 
3.  Accounting and Reporting Changes
 
In February 2007, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 159, The Fair Value Option for Financial Assets and Financial Liabilities Including an amendment of FASB Statement No. 115, which permits election of fair value to measure many financial instruments and certain other items.  SFAS No. 159 is effective for Millennium beginning in 2008.  Millennium is currently evaluating whether it will elect the fair value option for any of its eligible financial instruments and other items.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements.  The new standard defines fair value, establishes a framework for its measurement and expands disclosures about such measurements.  For Millennium, the standard will be effective beginning in 2008.  Millennium does not expect the application of SFAS No. 157 to have a material effect on its consolidated financial statements.

Millennium adopted the provisions of FASB Interpretation (“FIN”) No. 48, Accounting for Uncertainty in Income Taxes, on January 1, 2007.  As a result of the implementation of FIN No. 48, Millennium recognized a $47 million increase in the liability related to uncertain income tax positions, a $4 million increase in deferred tax assets and a $43 million increase of the January 1, 2007 balance of retained deficit (see Note 12).

5

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

4.       Discontinued Operations
 
On May 15, 2007, Millennium completed the sale of its worldwide inorganic chemicals business in a transaction valued at $1.3 billion including the acquisition of working capital and assumption of certain liabilities directly related to the business.
 
The following represent the elements of cash flow for the six months ended June 30, 2007 related to the sale of the inorganic chemicals business:

Millions of dollars
     
Gross sales proceeds
  $
1,143
 
Cash and cash equivalents sold
    (37 )
Costs related to the sale
    (17 )
Net proceeds from sale of discontinued operations
before required repayment of debt
   
1,089
 
Debt required to be repaid
    (99 )
Net proceeds from sale of discontinued operations
  $
990
 


The operations of the inorganic chemicals business have been classified as discontinued operations in the consolidated statements of income and cash flows, and the assets and associated liabilities have been classified as held for sale in the consolidated balance sheets.

Amounts included in income from discontinued operations are summarized as follows:

   
For the three months ended
June 30,
   
For the six months ended
June 30,
 
Millions of dollars
 
2007
   
2006
   
2007
   
2006
 
Sales and other operating revenues
  $
181
    $
357
    $
514
    $
696
 
 
Gain on sale of discontinued operations
  $
337
    $
- -
    $
337
    $
- -
 
Other income (loss) from discontinued operations
    (2 )    
27
     
18
     
38
 
Provision for (benefit from) income taxes
   
52
      (42 )    
58
      (32 )
Income from discontinued operations,
  net of tax
  $
283
    $
69
    $
297
    $
70
 


The provision for income taxes in the three months and six months ended June 30, 2007 primarily reflects the effect of a higher tax basis in the stock of a subsidiary included in the sale, which resulted in a lower taxable gain.  Income taxes payable related to the sale were $48 million.


6

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

4.       Discontinued Operations – (Continued)
 
The assets and liabilities of the inorganic chemicals business classified as held for sale are summarized as follows:

Millions of dollars
 
December 31,
2006
 
Cash
  $
45
 
Inventories
   
353
 
Other current assets
   
263
 
Total current assets
   
661
 
Property, plant and equipment, net
   
522
 
Goodwill, net
   
55
 
Other noncurrent assets, net
   
117
 
Total long-term assets
   
694
 
 
Total assets
  $
1,355
 
         
Current maturities of long-term debt
  $
4
 
Other current liabilities
   
331
 
Total current liabilities
   
335
 
 
Long-term debt
   
82
 
Other noncurrent liabilities
   
239
 
Minority interest
   
40
 
Total long-term liabilities
   
361
 
 
Total liabilities
  $
696
 


Additionally, accumulated other comprehensive loss includes a loss of $6 million related to discontinued operations at December 31, 2006.
 
 
5.       Notes Receivable from Equistar Chemicals, LP
 
On June 22, 2007 Millennium received promissory notes from and advanced $500 million to Equistar Chemicals, LP (together with its consolidated subsidiaries, “Equistar”).  The notes mature on December 21, 2007 or earlier upon demand, and bear interest at the London Interbank Offered Rate (“LIBOR”) plus 1.75%.  Interest is due quarterly.
 

7

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

6.       Investment in Equistar Chemicals, LP
 
Equistar is owned 70.5% by Lyondell and 29.5% by Millennium.  Millennium and Equistar are wholly owned subsidiaries of Lyondell.  Millennium accounts for its investment in Equistar using the equity method.  As a partnership, Equistar is not subject to federal income taxes.
 
Summarized financial information for Equistar follows:
 
Millions of dollars
 
June 30,
2007
   
December 31,
2006
 
BALANCE SHEETS
           
Total current assets
  $
2,111
    $
2,158
 
Property, plant and equipment, net
   
2,812
     
2,846
 
Investments and other assets, net
   
321
     
355
 
Total assets
  $
5,244
    $
5,359
 
                 
Notes payable – Millennium Chemicals Inc.
  $
500
    $
- -
 
Other current liabilities
   
1,283
     
1,217
 
Long-term debt
   
1,553
     
2,160
 
Other liabilities and deferred revenues
   
384
     
378
 
Partners’ capital
   
1,524
     
1,604
 
Total liabilities and partners’ capital
  $
5,244
    $
5,359
 

 
   
For the three months ended
June 30,
   
For the six months ended
June 30,
 
Millions of dollars
 
2007
   
2006
   
2007
   
2006
 
STATEMENTS OF INCOME
                       
Sales and other operating revenues
  $
3,534
    $
3,278
    $
6,403
    $
6,314
 
Cost of sales
   
3,362
     
3,028
     
6,100
     
5,698
 
Selling, general and administrative expenses
   
72
     
61
     
131
     
109
 
Research and development expenses
   
9
     
9
     
18
     
17
 
Operating income
   
91
     
180
     
154
     
490
 
Interest expense, net
    (50 )     (52 )     (103 )     (105 )
Other expense, net
    (33 )    
- -
      (32 )     (1 )
Net income
  $
8
    $
128
    $
19
    $
384
 
 

8

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

7.       Inventories
 
Inventories consisted of the following components:
 
Millions of dollars
 
June 30,
2007
   
December 31,
2006
 
Finished goods
  $
62
    $
63
 
Work-in-process
   
19
     
15
 
Raw materials
   
5
     
4
 
Materials and supplies
   
6
     
5
 
Total inventories
  $
92
    $
87
 

 
8.       Property, Plant and Equipment
 
The components of property, plant and equipment, at cost, and the related accumulated depreciation were as follows:
 
Millions of dollars
 
June 30,
2007
   
December 31,
2006
 
Land
  $
2
    $
2
 
Manufacturing facilities and equipment
   
330
     
342
 
Construction in progress
   
16
     
16
 
Total property, plant and equipment
   
348
     
360
 
Less accumulated depreciation
    (227 )     (231 )
Property, plant and equipment, net
  $
121
    $
129
 

 
Depreciation and amortization expense is summarized as follows:
 
   
For the three months ended
June 30,
   
For the six months ended
June 30,
 
Millions of dollars
 
2007
   
2006
   
2007
   
2006
 
Property, plant and equipment
  $
10
    $
4
    $
14
    $
9
 
Other
   
1
     
2
     
3
     
4
 
Total depreciation and amortization
  $
11
    $
6
    $
17
    $
13
 

 
 
9.       Accounts Payable
 
Accounts payable at June 30, 2007 and December 31, 2006 included liabilities in the amounts of $2 million and $1 million, respectively, for checks issued in excess of associated bank balances but not yet presented for collection.

 
9

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

10.       Long-Term Debt
 
Long-term debt consisted of the following:
 
Millions of dollars
 
June 30,
2007
   
December 31,
2006
 
Senior Notes due 2008, 9.25%
  $
- -
    $
375
 
Senior Debentures due 2026, 7.625%
   
241
     
245
 
Convertible Senior Debentures due 2023, 4%
   
150
     
150
 
Other
   
- -
      (3 )
Total
   
391
     
767
 
Less current maturities
   
- -
     
- -
 
Total long-term debt, net
  $
391
    $
767
 

 
During the first six months of 2007, Millennium repaid the remaining $373 million principal amount of its 9.25% Senior Notes due 2008, paying a premium of $13 million, and $4 million principal amount of its 7.625% Debentures due 2026.  In connection with the repayment of the 9.25% Senior Notes, Millennium terminated interest rate swap agreements in the notional amount of $175 million and recorded a loss of $2 million.  As a result of the repayment of the 9.25% Senior Notes, Millennium is no longer prohibited from making certain restricted payments, including cash dividends to Lyondell, nor is it required to maintain financial ratios.
 
As of June 30, 2007, based on a quarterly test related to the price of Lyondell common stock, Millennium’s 4% Convertible Senior Debentures were convertible into Lyondell common stock at a conversion rate of 75.763 Lyondell shares per one thousand dollar principal amount of the Debentures.  The principal amount of Debentures that had been converted into shares of Lyondell common stock as of June 30, 2007 was not significant.
 
Millennium has outstanding letters of credit of $14 million at June 30, 2007.  Related cash collateral of $14 million is included in “Other assets, net” at June 30, 2007.
 
Amortization of debt issuance costs of less than $1 million in each of the three- and six-month periods ended June 30, 2007 and 2006 is included in interest expense in the Consolidated Statements of Income.
 
 
11.       Pension and Other Postretirement Benefits
 
Net periodic pension benefits, which are provided to U.S. employees, included the following cost components:
 
   
For the three months ended
June 30,
   
For the six months ended
June 30,
 
Millions of dollars
 
2007
   
2006
   
2007
   
2006
 
Service cost
  $
1
    $
1
    $
2
    $
2
 
Interest cost
   
8
     
8
     
16
     
16
 
Recognized return on plan assets
    (9 )     (9 )     (18 )     (18 )
Amortization
   
1
     
4
     
4
     
8
 
Net periodic pension benefit cost
  $
1
    $
4
    $
4
    $
8
 

 

10

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

11.           Pension and Other Postretirement Benefits –  (Continued)
 
Net periodic other postretirement benefits, which are provided to U.S. employees, were net credits of less than $1 million in each of the three month periods ended June 30, 2007 and 2006 and $1 million and $2 million, respectively, in the six-month periods ended June 30, 2007 and 2006.  A reduction of benefits in 2004 resulted in a net prior service benefit that is amortized to income as a credit of $4 million annually.
 
 
12.       Income Taxes
 
Certain income tax returns of Millennium and various of its subsidiaries are under examination by the Internal Revenue Service (“IRS”) and various non-U.S. and state tax authorities.  In many cases, these audits may result in proposed assessments by the tax authorities.  Millennium believes that its tax positions comply with applicable tax law and intends to defend its positions through appropriate administrative and judicial processes.
 
Tax benefits totaling $173 million relating to uncertain tax positions taken in prior years, including $44 million pertaining to discontinued operations, were unrecognized as of January 1, 2007 (see Note 3).  As a result of the sale of the inorganic chemicals business, this amount decreased by the $44 million.  There were no other material changes to the amount of unrecognized benefits during the six months ended June 30, 2007.
 
A substantial portion of these uncertainties relate to passive foreign income for the years 1997 to 2001 and related capital loss benefits that were subsequently recognized.  IRS audit examination of the matter has been completed, and it is now in the administrative appeals process.  It is reasonably possible that the matter may be settled in 2007 and result in a significant reduction of the amount of unrecognized tax benefits.  With the exception of the preceding issue, Millennium is no longer subject to any significant income tax examinations by tax authorities for years prior to 2002.
 
Millennium recognizes interest accrued related to uncertain income tax positions in interest expense.  Millennium’s accrued liability for interest as of January 1, 2007 was $86 million.  The noncurrent portion of liabilities for uncertain income tax positions and related interest are classified as “Other liabilities” in the consolidated balance sheets.
 
The income tax provision for the six months ended June 30, 2007 was a benefit of $12 million on a loss before income taxes of $28 million.  The effective income tax rate for the first six months of 2007 was 42%, compared to an estimated income tax rate of 34% used in the first quarter 2007, due primarily to a $2 million benefit from newly-enacted Texas state legislation, allowing the carryforward of certain tax losses for state income tax purposes.  The income tax provision for the six months ended June 30, 2006 was a benefit of $5 million on income before taxes of $72 million.  This income tax benefit primarily reflected the effects of favorable settlements of and changes in estimates for prior year items during the six months ended June 30, 2006.
 
 
13.       Other Income (Expense), Net
 
Millennium’s other income (expense), net, in the second quarter and first six months of 2007 included debt prepayment charges of $16 million, while the second quarter 2006 included a $19 million credit related to the reversal of interest accruals for prior year income tax issues that offset an accrual of $18 million in the first quarter 2006, for a net benefit of $1 million in the first six months of 2006.  The reversals reflected a favorable settlement of the prior year tax issues.  See Note 12.
 

11

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

14.       Commitments and Contingencies
 
Asset Retirement Obligation—Millennium believes that there are asset retirement obligations associated with some of its facilities, but that the present value of those obligations normally is not material in the context of an indefinite expected life of the facilities.  Millennium continually reviews the optimal future alternatives for its facilities.  The amount and timing of costs, if any, that may be incurred as a result of such reviews are not known, and no decisions have been reached, but if a decision were reached, in accordance with local laws and customs, to retire one or more facilities in the foreseeable future, the asset retirement costs could range from $0 to $30 million, depending upon the scope of the required work and other factors.  At June 30, 2007 and December 31, 2006, no liability had been recognized for asset retirement obligations.  Any decision to retire a facility would result in costs, including employment related costs.
 
Environmental Remediation—Millennium’s accrued liability for future environmental remediation costs at current and former plant sites and other remediation sites totaled $153 million and $148 million as of June 30, 2007 and December 31, 2006, respectively.  The remediation expenditures are expected to occur over a number of years, and not to be concentrated in any single year.  In the opinion of management, there is no material estimable range of reasonably possible loss in excess of the liabilities recorded for environmental remediation.  However, it is possible that new information about the sites for which the accrual has been established, new technology or future developments such as involvement in investigations by regulatory agencies, could require Millennium to reassess its potential exposure related to environmental matters.
 
The following table summarizes the activity in Millennium’s accrued environmental liability for the six months ended June 30:
 
Millions of dollars
 
2007
   
2006
 
Balance at January 1
  $
148
    $
145
 
Additional provisions
   
10
     
4
 
Amounts paid
    (5 )     (5 )
Balance at June 30
  $
153
    $
144
 

 
The liabilities for individual sites range from less than $1 million to $112 million.  The $112 million liability relates to the Kalamazoo River Superfund Site.
 
A Millennium subsidiary has been identified as a Potential Responsible Party (“PRP”) with respect to the Kalamazoo River Superfund Site.  The site involves cleanup of river sediments and floodplain soils contaminated with polychlorinated biphenyls, cleanup of former paper mill operations, and cleanup and closure of landfills associated with the former paper mill operations.  In 2000, the Kalamazoo River Study Group (the “KRSG”), of which the Millennium subsidiary and other PRPs are members, submitted to the State of Michigan a Draft Remedial Investigation and Draft Feasibility Study, which evaluated a number of remedial options for the river.  The estimated costs for these remedial options ranged from $0 to $2.5 billion.
 
At the end of 2001, the U.S. Environmental Protection Agency (“EPA”) took lead responsibility for the river portion of the site at the request of the State of Michigan.  In 2004, the EPA initiated a confidential process to facilitate discussions among the agency, the Millennium subsidiary, other PRPs, the Michigan Departments of Environmental Quality and Natural Resources, and certain federal natural resource trustees about the need for additional investigation activities and different possible approaches for addressing the contamination in and along the Kalamazoo River.  These discussions are continuing.
 

12

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

14.       Commitments and Contingencies – (Continued)
 
As of June 30, 2007, the probable future remediation spending associated with the river cannot be determined with certainty.  Although the KRSG study identified a broad range of remedial options, not all of those options would represent reasonably possible outcomes.  Management does not believe that it can identify a single remedy among those options that would represent the highest-cost reasonably possible outcome.  However, in 2004, Millennium recognized a liability representing Millennium’s interim allocation of 55% of the $73 million total of estimated cost of riverbank stabilization, recommended as the preferred remedy in 2000 by the KRSG study, and of certain other costs.
 
New information has since been obtained about regulatory oversight costs and other remediation costs, including a proposed remedy to be applied to a specific portion of the river.  As a result, Millennium recognized $8 million in the first six months of 2007 for additional estimated probable future remediation costs.  The activities related to the specific portion of the river are expected to be completed in 3 to 4 years and may provide Millennium with a basis for estimating the probable future remediation cost of the Kalamazoo River.  At June 30, 2007, the balance of this liability was $65 million.
 
In addition, in 2004, Millennium recognized a liability primarily related to Millennium’s estimated share of remediation costs for two former paper mill sites and associated landfills, which are also part of the Kalamazoo River Superfund Site.  At June 30, 2007, the balance of the liability was $47 million.  Although no final agreement has been reached as to the ultimate remedy for these locations, Millennium has begun remediation activity related to these sites.
 
Millennium’s ultimate liability for the Kalamazoo River Superfund Site will depend on many factors that have not yet been determined, including the ultimate remedy selected, the determination of natural resource damages, the number and financial viability of the other PRPs, and the determination of the final allocation among the PRPs.
 
The balance, at June 30, 2007, of remediation liabilities related to Millennium sites other than the Kalamazoo River Superfund Site was $41 million.
 
Litigation—Together with alleged past manufacturers of lead-based paint and lead pigments for use in paint, Millennium has been named as a defendant in various legal proceedings alleging personal injury, property damage, and remediation costs allegedly associated with the use of these products.  The majority of these legal proceedings assert unspecified monetary damages in excess of the statutory minimum and, in certain cases, equitable relief such as abatement of lead-based paint in buildings.  Legal proceedings relating to lead pigment or paint are in various trial stages and post-dismissal settings, some of which are on appeal.
 
One legal proceeding relating to lead pigment or paint was tried in 2002.  On October 29, 2002, the judge in that case declared a mistrial after the jury declared itself deadlocked.  The sole issue before the jury was whether lead pigment in paint in and on Rhode Island buildings constituted a “public nuisance.”  The re-trial of this case began on November 1, 2005.  On February 22, 2006, a jury returned a verdict in favor of the State of Rhode Island finding that the cumulative presence of lead pigments in paints and coatings on buildings in the state constitutes a public nuisance; that a Millennium subsidiary, Millennium Holdings, LLC, and other defendants either caused or substantially contributed to the creation of the public nuisance; and that those defendants, including the Millennium subsidiary, should be ordered to abate the public nuisance.  On February 28, 2006, the judge held that the state could not proceed with its claim for punitive damages.  On February 26, 2007, the court issued its decision denying the post-verdict motions of the defendants, including Millennium, for a mistrial or a new trial.  The court concluded that it would enter an order of abatement and appoint a special master to assist the court in determining the scope of the abatement remedy.  On March 16, 2007, the court entered a final judgment on the jury’s verdict.  On March 20, 2007, Millennium filed its notice of appeal with the Rhode Island Supreme Court.
 
13

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
 
14.       Commitments and Contingencies – (Continued)
 
Millennium’s defense costs to date for lead-based paint and lead pigment litigation largely have been covered by insurance.  Millennium has insurance policies that potentially provide approximately $1 billion in indemnity coverage for lead-based paint and lead pigment litigation.  Millennium’s ability to collect under the indemnity coverage would depend upon, among other things, the resolution of certain potential coverage defenses that the insurers are likely to assert and the solvency of the various insurance carriers that are part of the coverage block at the time of such a request.
 
While Millennium believes that it has valid defenses to all the lead-based paint and lead pigment proceedings and is vigorously defending them, litigation is inherently subject to many uncertainties.  Any liability that Millennium may ultimately incur, net of any insurance or other recoveries, cannot be estimated at this time.
 
Guarantees—Millennium continues to guarantee certain obligations related to the sold inorganic chemicals business until such time as the buyer completes certain procedures to replace Millennium as guarantor.  The guarantees, principally with respect to leases of offices, research facilities and railcars, have a total potential obligation of approximately $60 million over their remaining term.  Millennium does not expect that any payments will be required under these guarantees.
 
Indemnification—Millennium and its joint ventures are parties to various indemnification arrangements, including arrangements entered into in connection with acquisitions, divestitures and the formation of joint ventures.  For example, Millennium entered into indemnification arrangements in connection with its demerger from Hanson plc, and Equistar and its owner companies (including Millennium) entered into indemnification arrangements in connection with the formation of Equistar.  Pursuant to these arrangements, Millennium and its joint ventures provide indemnification to and/or receive indemnification from other parties in connection with liabilities that may arise in connection with the transactions and in connection with activities prior to completion of the transactions.  These indemnification arrangements typically include provisions pertaining to third party claims relating to environmental and tax matters and various types of litigation.  As of June 30, 2007, Millennium has not accrued any significant amounts for such indemnification obligations, and is not aware of other circumstances that would be likely to lead to significant future indemnification claims against Millennium.  Millennium cannot determine with certainty the potential amount of future payments under the indemnification arrangements until events arise that would trigger a liability under the arrangements.
 
Other—Millennium and its joint ventures are, from time to time, defendants in lawsuits and other commercial disputes, some of which are not covered by insurance.  Many of these suits make no specific claim for relief.  Although final determination of any liability and resulting financial impact with respect to any such matters cannot be ascertained with any degree of certainty, management does not believe that any ultimate uninsured liability resulting from these matters in which it, its subsidiaries or its joint ventures currently are involved will, individually or in the aggregate, have a material adverse effect on the financial position, liquidity or results of operations of Millennium.
 
General—In the opinion of management, the matters discussed in this note, other than potential future liabilities for environmental remediation which amounts cannot be estimated, are not expected to have a material adverse effect on the financial position or liquidity of Millennium.  However, the adverse resolution in any reporting period of one or more of the matters discussed in this note could have a material impact on Millennium’s results of operations for that period, which may be mitigated by contribution or indemnification obligations of others, or by any insurance coverage that may be available.
 

14

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

15.       Comprehensive Income
 
The components of comprehensive income were as follows:
 
   
For the three months ended
June 30,
   
For the six months ended
June 30,
 
Millions of dollars
 
2007
   
2006
   
2007
   
2006
 
Net income
  $
266
    $
114
    $
281
    $
147
 
Other comprehensive income, net of tax:
                               
Continuing operations:
                               
Foreign currency translation
   
- -
     
1
     
- -
     
1
 
Amortization of actuarial and investment loss
included in net periodic pension cost
   
3
     
- -
     
3
     
- -
 
 
Discontinued operations:
                               
Foreign currency translation
   
7
     
8
     
16
     
23
 
Amortization of actuarial and investment loss
included in net periodic pension cost
   
2
     
- -
     
2
     
- -
 
Sale of discontinued operations
    (63 )    
- -
      (63 )    
- -
 
Total other comprehensive income
    (51 )    
9
      (42 )    
24
 
Comprehensive income
  $
215
    $
123
    $
239
    $
171
 

 
 
16.       Segment and Related Information
 
Millennium, a wholly owned subsidiary of Lyondell, operates in two reportable segments:

·  
Ethylene, co-products and derivatives (“EC&D”), including Millennium’s acetyls business, which produces vinyl acetate monomer (“VAM”), acetic acid and methanol; and Millennium’s equity investment in Equistar, which produces primarily ethylene, co-products such as propylene, butadiene and aromatics, and derivatives such as ethylene oxide, ethylene glycol and polyethylene; and
·  
Fragrance and flavors chemicals, which includes terpene-based fragrance ingredients and flavor ingredients.
 
On May 15, 2007, Millennium completed the sale of its worldwide inorganic chemicals business (see Note 4).
 


15

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

16.       Segment and Related Information – (Continued)
 
Summarized financial information concerning reportable segments is shown in the following table for the periods presented:
 
Millions of dollars
 
EC&D
   
Fragrance & Flavors
   
Other
   
Total
 
For the three months ended June 30, 2007
                       
Sales and other operating revenues
  $
131
    $
28
    $
2
    $
161
 
Operating income (loss)
   
15
     
2
      (21 )     (4 )
Income from equity investment
   
3
     
- -
     
- -
     
3
 
                                 
For the three months ended June 30, 2006
                               
Sales and other operating revenues
  $
122
    $
27
    $
4
    $
153
 
Operating income (loss)
   
9
     
2
      (4 )    
7
 
Income from equity investment
   
38
     
- -
     
- -
     
38
 
                                 
For the six months ended June 30, 2007
                               
Sales and other operating revenues
  $
253
    $
56
    $
4
    $
313
 
Operating income (loss)
   
36
     
5
      (28 )    
13
 
Income from equity investment
   
6
     
- -
     
- -
     
6
 
                                 
For the six months ended June 30, 2006
                               
Sales and other operating revenues
  $
238
    $
53
    $
6
    $
297
 
Operating income (loss)
   
1
     
3
      (11 )     (7 )
Income from equity investment
   
113
     
- -
     
- -
     
113
 

 
Operating income (loss) in the “Other” column above includes a business that is not a reportable segment and costs not allocated to Millennium’s business segments, including costs from predecessor businesses.
 

16

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

17.       Subsequent Event
 
 
On July 16, 2007, Lyondell, Basell AF, a Luxembourg company (“Basell”), and BIL Acquisition Holdings Limited, a Delaware corporation and a wholly owned subsidiary of Basell (“Merger Sub”) entered into an agreement and plan of merger pursuant to which Merger Sub will be merged with and into Lyondell with Lyondell continuing as the surviving corporation and a wholly owned subsidiary of Basell.  Pursuant to the merger, each outstanding share of Lyondell’s common stock will be converted into the right to receive $48 per share in cash.  The proposed merger is expected to close within the next several months.
 
The merger agreement restricts the ability of Lyondell and its subsidiaries, including Millennium and Equistar, to take specified actions without Basell’s approval including, among other things, making significant acquisitions, dispositions or investments, making certain significant capital expenditures not contemplated by the current capital plan, and entering into certain material contracts.
 
As a result of the proposed merger, Millennium’s 4% convertible debentures will be convertible at the conversion rate into the $48 cash per share merger consideration.  In addition, depending on the financing structure of the merger, the Notes due 2026 may be amended or terminated.
 
 
18.           Supplemental Guarantor Information
 
 
Millennium America Inc. (“Millennium America”), a 100% owned indirect subsidiary of Millennium, is a holding company for all of Millennium’s continuing and discontinued operating subsidiaries other than the operations in the United Kingdom, France, Brazil and Australia, all of which are discontinued.  Millennium America is the issuer of the 7.625% Senior Debentures and Millennium is the issuer of the 4% Convertible Senior Debentures.  Millennium America fully and unconditionally guarantees all obligations under the 4% Convertible Senior Debentures.  The 7.625% Senior Debentures are fully and unconditionally guaranteed by Millennium.  The following condensed consolidating financial information presents supplemental information for Millennium Chemicals Inc., the parent, and Millennium America as of June 30, 2007 and December 31, 2006 and for the three- and six-month periods ended June 30, 2007 and 2006.
 

17

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

CONDENSED CONSOLIDATING FINANCIAL INFORMATION

BALANCE SHEET
 
As of June 30, 2007
 
 
Millions of dollars
 
Millennium
Chemicals Inc.
   
Millennium
America Inc.
   
Non-Guarantor
Subsidiaries
   
Eliminations
   
Millennium
Chemicals Inc.
and Subsidiaries
 
                               
Inventories
  $
- -
    $
- -
    $
92
    $
- -
    $
92
 
Notes receivable from
Equistar Chemicals, LP
   
200
     
300
     
- -
     
- -
     
500
 
Other current assets
   
- -
     
17
     
209
     
- -
     
226
 
Property, plant and equipment, net
   
- -
     
- -
     
121
     
- -
     
121
 
Investment in Equistar Chemicals, LP
   
- -
     
- -
     
446
     
- -
     
446
 
Investment in subsidiaries
   
298
     
1,650
     
- -
      (1,948 )    
- -
 
Goodwill, net
   
- -
     
- -
     
49
     
- -
     
49
 
Other assets, net
   
2
     
13
     
56
     
- -
     
71
 
Total assets
  $
500
    $
1,980
    $
973
    $ (1,948 )   $
1,505
 
                                         
Current liabilities
  $
1
    $
2
    $
251
    $
- -
    $
254
 
Long-term debt
   
150
     
241
     
- -
     
- -
     
391
 
Other liabilities
   
- -
     
- -
     
255
     
- -
     
255
 
Deferred income taxes
   
- -
     
- -
     
261
     
- -
     
261
 
Due to parent and affiliates, net
   
10
     
560
      (570 )    
- -
     
- -
 
Total liabilities
   
161
     
803
     
197
     
- -
     
1,161
 
Minority interest
   
- -
     
- -
     
5
     
- -
     
5
 
Stockholder’s equity
   
339
     
1,177
     
771
      (1,948 )    
339
 
Total liabilities
  and stockholder’s equity
  $
500
    $
1,980
    $
973
    $ (1,948 )   $
1,505
 


18

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

CONDENSED CONSOLIDATING FINANCIAL INFORMATION

BALANCE SHEET
 
As of December 31, 2006
 
 
Millions of dollars
 
Millennium
Chemicals Inc.
   
Millennium
America Inc.
   
Non-Guarantor
Subsidiaries
   
Eliminations
   
Millennium
Chemicals Inc.
and Subsidiaries
 
                               
Inventories
  $
- -
    $
- -
    $
87
    $
- -
    $
87
 
Other current assets
   
- -
     
62
     
200
     
- -
     
262
 
Current assets held for sale
   
- -
     
- -
     
661
     
- -
     
661
 
Property, plant and equipment, net
   
- -
     
- -
     
129
     
- -
     
129
 
Investment in Equistar Chemicals, LP
   
- -
     
- -
     
470
     
- -
     
470
 
Investment in subsidiaries
   
310
     
497
     
- -
      (807 )    
- -
 
Goodwill, net
   
- -
     
- -
     
49
     
- -
     
49
 
Other assets, net
    (2 )     (2 )    
66
     
- -
     
62
 
Due from parent and affiliates, net
   
- -
     
368
     
- -
      (368 )    
- -
 
Long-term assets held for sale
   
- -
     
- -
     
694
     
- -
     
694
 
Total assets
  $
308
    $
925
    $
2,356
    $ (1,175 )   $
2,414
 
                                         
Current liabilities
  $
1
    $
4
    $
169
    $
- -
    $
174
 
Current liabilities associated
with assets held for sale
   
- -
     
- -
     
335
     
- -
     
335
 
Long-term debt
   
150
     
617
     
- -
     
- -
     
767
 
Other liabilities
   
- -
     
3
     
378
     
- -
     
381
 
Deferred income taxes
   
- -
     
- -
     
248
     
- -
     
248
 
Due to parent and affiliates, net
   
14
     
- -
     
354
      (368 )    
- -
 
Long-term liabilities associated
    with assets held for sale
   
- -
     
- -
     
361
     
- -
     
361
 
Total liabilities
   
165
     
624
     
1,845
      (368 )    
2,266
 
Minority interest
   
- -
     
- -
     
5
     
- -
     
5
 
Stockholder’s equity
   
143
     
301
     
506
      (807 )    
143
 
Total liabilities and
  stockholder’s equity
  $
308
    $
925
    $
2,356
    $ (1,175 )   $
2,414
 


19

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

CONDENSED CONSOLIDATING FINANCIAL INFORMATION

STATEMENT OF INCOME
 
For the Three Months Ended June 30, 2007
 
Millions of dollars
 
Millennium
Chemicals Inc.
   
Millennium
America Inc.
   
Non-Guarantor
Subsidiaries
   
Eliminations
   
Millennium
Chemicals Inc.
and Subsidiaries
 
                               
Sales and other operating revenues
  $
- -
    $
- -
    $
161
    $
- -
    $
161
 
Cost of sales
   
- -
     
- -
     
142
     
- -
     
142
 
Selling, general
and administrative expenses
   
- -
     
- -
     
22
     
- -
     
22
 
Research and development expenses
   
- -
     
- -
     
1
     
- -
     
1
 
Operating loss
   
- -
     
- -
      (4 )    
- -
      (4 )
Interest expense, net
   
- -
      (10 )     (3 )    
- -
      (13 )
Intercompany interest
income (expense), net
   
- -
     
28
      (28 )    
- -
     
- -
 
Income from equity investment in
Equistar Chemicals, LP
   
- -
     
- -
     
3
     
- -
     
3
 
Equity in
income of subsidiaries
   
266
     
873
     
- -
      (1,139 )    
- -
 
Other income (expense), net
   
- -
      (17 )    
1
     
- -
      (16 )
Benefit from
(provision for) income taxes
   
- -
      (305 )    
318
     
- -
     
13
 
Income from discontinued
operations, net of tax
   
- -
     
- -
     
283
     
- -
     
283
 
Net income
  $
266
    $
569
    $
570
    $ (1,139 )   $
266
 


STATEMENT OF INCOME
 
For the Three Months Ended June 30, 2006
 
Millions of dollars
 
Millennium
Chemicals Inc.
   
Millennium
America Inc.
   
Non-Guarantor
Subsidiaries
   
Eliminations
   
Millennium
Chemicals Inc.
and Subsidiaries
 
                               
Sales and other operating revenues
  $
- -
    $
- -
    $
153
    $
- -
    $
153
 
Cost of sales
   
- -
     
- -
     
134
     
- -
     
134
 
Selling, general
and administrative expenses
   
- -
     
- -
     
11
     
- -
     
11
 
Research and development expenses
   
- -
     
- -
     
1
     
- -
     
1
 
Operating income
   
- -
     
- -
     
7
     
- -
     
7
 
Interest expense, net
    (1 )     (15 )     (2 )    
- -
      (18 )
Intercompany interest
income (expense), net
   
- -
     
27
      (27 )    
- -
     
- -
 
Other income, net
   
- -
     
- -
     
20
     
- -
     
20
 
Income from equity investment in
Equistar  Chemicals, LP
   
- -
     
- -
     
38
     
- -
     
38
 
Equity in income of subsidiaries
   
115
     
18
      (54 )     (79 )    
- -
 
Benefit from
(provision) for income taxes
   
- -
     
16
      (18 )    
- -
      (2 )
Income from discontinued
operations, net of tax
   
- -
     
- -
     
69
     
- -
     
69
 
Net income
  $
114
    $
46
    $
33
    $ (79 )   $
114
 


20

MILLENNIUM CHEMICALS INC.
 
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

CONDENSED CONSOLIDATING FINANCIAL INFORMATION

STATEMENT OF INCOME
 
For the Six Months Ended June 30, 2007
 
Millions of dollars
 
Millennium
Chemicals Inc.
   
Millennium
America Inc.
   
Non-Guarantor
Subsidiaries
   
Eliminations
   
Millennium
Chemicals Inc.
and Subsidiaries
 
                               
Sales and other operating revenues
  $
- -
    $
- -
    $
313
    $
- -
    $
313
 
Cost of sales
   
- -
     
- -
     
264
     
- -
     
264
 
Selling, general
and administrative expenses
   
- -
     
- -
     
34
     
- -
     
34
 
Research and development expenses
   
- -
     
- -
     
2
     
- -
     
2
 
Operating income
   
- -
     
- -
     
13
     
- -
     
13
 
Interest expense, net
    (4 )     (23 )     (4 )    
- -
      (31 )
Intercompany interest
income (expense), net
   
- -